These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
47 related articles for article (PubMed ID: 22241725)
1. Targeted radionuclide therapy in combined-modality regimens. Gill MR; Falzone N; Du Y; Vallis KA Lancet Oncol; 2017 Jul; 18(7):e414-e423. PubMed ID: 28677577 [TBL] [Abstract][Full Text] [Related]
2. The evidence base for the use of internal dosimetry in the clinical practice of molecular radiotherapy. Strigari L; Konijnenberg M; Chiesa C; Bardies M; Du Y; Gleisner KS; Lassmann M; Flux G Eur J Nucl Med Mol Imaging; 2014 Oct; 41(10):1976-88. PubMed ID: 24915892 [TBL] [Abstract][Full Text] [Related]
4. Peptide receptor radionuclide therapy using radiolabeled somatostatin analogs: focus on future developments. Bison SM; Konijnenberg MW; Melis M; Pool SE; Bernsen MR; Teunissen JJ; Kwekkeboom DJ; de Jong M Clin Transl Imaging; 2014; 2(1):55-66. PubMed ID: 24765618 [TBL] [Abstract][Full Text] [Related]
5. Defining the role for dosimetry and radiobiology in combination therapies. Bardiès M; Flux GD Eur J Nucl Med Mol Imaging; 2013 Jan; 40(1):4-5. PubMed ID: 23143662 [No Abstract] [Full Text] [Related]
6. Lutetium-labelled peptides for therapy of neuroendocrine tumours. Kam BL; Teunissen JJ; Krenning EP; de Herder WW; Khan S; van Vliet EI; Kwekkeboom DJ Eur J Nucl Med Mol Imaging; 2012 Feb; 39 Suppl 1(Suppl 1):S103-12. PubMed ID: 22388631 [TBL] [Abstract][Full Text] [Related]
7. Radionuclide Therapy for Neuroendocrine Tumors. Cives M; Strosberg J Curr Oncol Rep; 2017 Feb; 19(2):9. PubMed ID: 28220446 [TBL] [Abstract][Full Text] [Related]
8. Radiation dosimetry is a necessary ingredient for a perfectly mixed molecular radiotherapy cocktail. Savolainen S; Konijnenberg M; Bardiès M; Lassmann M; Strigari L; Chiesa C; Chiti A; Reijonin V; Flux G Eur J Nucl Med Mol Imaging; 2012 Mar; 39(3):548-9. PubMed ID: 22241725 [No Abstract] [Full Text] [Related]
10. Cardiac Toxicity in a Patient Receiving Peptide Receptor Radionuclide Therapy. Hendifar AE; Delpassand ES; Kittleson MM; Tuli R Pancreas; 2018 Sep; 47(8):e55-e56. PubMed ID: 30113434 [No Abstract] [Full Text] [Related]
11. Treatment with Estorch M Rev Esp Med Nucl Imagen Mol; 2017; 36(2):69-71. PubMed ID: 28257748 [No Abstract] [Full Text] [Related]
12. 90Y/177Lu-DOTATATE therapy: survival of the fittest? Brans B; Mottaghy FM; Kessels A Eur J Nucl Med Mol Imaging; 2011 Oct; 38(10):1785-7. PubMed ID: 21755369 [No Abstract] [Full Text] [Related]
13. Clinical results of radionuclide therapy of neuroendocrine tumours with 90Y-DOTATATE and tandem 90Y/177Lu-DOTATATE: which is a better therapy option? Kunikowska J; Królicki L; Hubalewska-Dydejczyk A; Mikołajczak R; Sowa-Staszczak A; Pawlak D Eur J Nucl Med Mol Imaging; 2011 Oct; 38(10):1788-97. PubMed ID: 21553086 [TBL] [Abstract][Full Text] [Related]